Transdermal Allergy Immunotherapy Study Shows Promise As An Alternative to Injections
“Traditional Allergy Immunotherapy consists of multiple years of Injections (sub-cutaneous immunotherapy- (SCIT)). We now have preliminary evidence that supplying allergens through topical administration shows a decrease in IgE levels and may prove to be a viable alternative to allergy shots and the millions of people who are allergy sufferers. We are conducting more clinical trials and excited to expand on these initial results.”
President, Clarity Science
“Understanding all available treatment options, tailoring therapy to the individual, while being knowledgeable of the current opioid crisis is crucial in today’s environment. Outcomes from The OPERA Study demonstrate that there are alternative approaches that allow clinicians to successfully treat a patient’s pain while addressing and mitigating risks.”
President, Clarity Science
See informative results from our studies.
Current Scar Study
(TopicAl Silicone in RestorinG Scars and Burn Tissue – Evaluating Therapy)
Positive interim TARGET Results have been presented at leading conferences, including the 7th Joint Meeting of the European Tissue Repair Society & the Wound Healing Society held in Copenhagen, Denmark, among others.
Results from an interim analysis of our TARGET study (a scar and burn treatment study) show that adults using a prescribed topical scar and burn cream reported:
Reduced scar/burn size as measured by clinicians and as perceived by patients.
Reduced scar/burn interference with general activity, mood, sleep, and life enjoyment.
Reduced pain medication use.
Closed Pain Study
(Optimizing Patient Experience and Response to Topical Analgesics)
Positive interim OPERA Results have been presented at important conferences, including the 4th Annual International Conference on Opioids held at Harvard Medical School, among others.
Results from an interim analysis of our OPERA study (a pain study) show that patients with musculoskeletal and neuropathic pain using a prescribed topical analgesic reported:
Reduced pain severity for patients with neuropathic and musculoskeletal pain.
Reduced pain interference with general activity, mood, sleep, and life enjoyment.
Reduced number of primary pain complaints for arthritis, neuropathy, or radiculopathy.
Reduced use of over-the-counter medications, anti-inflammatory medications, and opioid analgesics.
Clarity presented statistically-significant interim data from our OPERA study, a pain management study.
Clarity presented data from our TARGET Study at APWCA.
Clarity was awarded First Place for Best Scientific Presentation/Data.
Clarity will present interim data from our OPERA study, a pain management study.
Clarity to Exhibit at AAAAI
November 2, 2015
TARGET Study Data to be Presented at APWCA
February 25, 2016
NIH Study Invitation
November 1, 2015
TARGET Study featured in the Journal of Wound Technology
January 5, 2016